Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

William Blair projects strong VENTURE-Oral trial results for Viking's VK2735, citing flexibility and market opportunity after ...

A supplement succeeds when it fits your life. PhenQ is meant to be simple: one capsule with breakfast, one with lunch.

Eli Lilly has rolled out a prefilled pen version of its weight-loss drug Mounjaro at the same price as vials, aiming to ...

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for ...

University of Utah-led research found those losing weight with Ozempic also lost about 10% of lean mass, though not ...

Leaders at Eli Lilly believe heavy investment in the company's manufacturing footprint “sets a high standard that newcomers ...

People who took the daily pill orforglipron lost 12 percent of body weight on average after 72 weeks, according to clinical ...

Digestion issues, fatigue, and high costs haven’t stopped some from finding power and transformation through GLP-1 ...

A transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.